Guadecitabine Sodium

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameGuadecitabine Sodium
Drug Alias NameGuadecitabina呱西他滨Decitabine deoxyguanosine dinucleotide鸟地西他滨Guadecitabinum +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesKidney Neoplasms +[27] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[25] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVan Andel Research InstituteUniversity Of Southern CaliforniaNational Cancer Institute +[6] 
Inactive CompaniesWeill Medical College of Cornell UniversityF. Hoffmann-La Roche LtdOtsuka Pharmaceutical Co Ltd
Active IndicationsMyelodysplastic SyndromesFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[19] 
Inactive IndicationsMyeloproliferative DisordersKidney NeoplasmsColorectal Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksKEGG